Insomnia

... AJNR - Sign In Page HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This item requires a subscription to American Journal of Neuroradiology Online.

Full Text Atlas of Sleep Medicine AJNR Am J Neuroradiol.2006; 27: 722-723.

This Article Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager To view this item, select one of the options below: Sign In User Name Sign in without cookies.

Can't get past this page?

Help with Cookies.

Need to Activate?

Password Remember my user name & password.

Forgot your user name or password?

Purchase Short-Term Access Pay per Article - You may access this article (from the computer you are currently using) for 7 days for US$10.00.

Pay for Admission - You may access all content in American Journal of Neuroradiology Online (from the computer you are currently using) for 7 days for US$25.00.

Regain Access - You can regain access to a recent Pay per Article or Pay for Admission purchase if your access period has not yet expired.

Sign Up Subscribe to the Journal - Subscribe to the print and/or online journal.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH Copyright © 2006 by the American Society of Neuroradiology.

...

...ba href=/insomnia/a/b and compulsive disorders in development, went public in December, offering 5 million shares at $11 per share.

Losses grew to $38.6 million, or $33.30 per share, from a loss of $13.6 million, or $38.08 per share, a year earlier.

Treating deferred stock as if it was converted into common shares at the date of issuance, net loss was $4.14 per share, compared with a loss of $3.94 last year.

The company posted no revenue in 2005.

Operating expenses ballooned to $39.9 million, from $13.8 million last year as research and development costs expanded more than threefold to nearly $29 million.

Analysts, on average, were expecting a loss of $2.96 per share on no revenue, according to a poll by Thomson Financial.

The company said as of Dec.

31 it had cash and investments of $104 million and no long term debt.

Shares of Somaxon fell 3 cents to close at $16.48 on the Nasdaq.

Subscribe to the paper for less than thirty cents a day!

Copyright Notice & Privacy Policy Place an ad ...

...ba href=/insomnia/a/b and compulsive disorders in development, went public in December, offering 5 million shares at $11 per share.

Losses grew to $38.6 million, or $33.30 per share, from a loss of $13.6 million, or $38.08 per share, a year earlier.

Treating deferred stock as if it was converted into common shares at the date of issuance, net loss was $4.14 per share, compared with a loss of $3.94 last year.

The story continues below...

This article Email this page Site Map...